Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.33 |
| ▸ | HTR2B | P41595 | 5/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1500329 | 0.91 | — | — | |
| SCHEMBL15107924 | 0.91 | — | — | |
| SCHEMBL3468818 | 0.91 | — | — | |
| SCHEMBL15107928 | 0.91 | — | — | |
| SCHEMBL15107313 | 0.91 | — | — | |
| SCHEMBL13037059 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL14741321 | 0.88 | — | — | |
| SCHEMBL19934934 | 0.80 | — | — | |
| SCHEMBL22415986 | 0.78 | — | — | |
| SCHEMBL13895920 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180078480-A1 | Methods and Compositions for Dag Mitigation | INVENTION DEVELOPMENT MANAGEMENT COMPANY, LLC | 2018-03-22 | — | — | US | disclosed |
| US-20180077899-A1 | Methods and Compositions for Dag Mitigation | INVENTION DEVELOPMENT MANAGEMENT COMPANY, LLC | 2018-03-22 | — | — | US | disclosed |
| US-20180077899-A1 | Methods and Compositions for Dag Mitigation | INVENTION DEVELOPMENT MANAGEMENT COMPANY, LLC | 2018-03-22 | — | — | US | disclosed |
| US-20180078480-A1 | Methods and Compositions for Dag Mitigation | INVENTION DEVELOPMENT MANAGEMENT COMPANY, LLC | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180077899-A1 | Methods and Compositions for Dag Mitigation | DAGLB, DAGLA, DGAT2 | HTR2C 1543/4885HTR2B 2451/4885GABRR1 4330/4885 |
| US-20180078480-A1 | Methods and Compositions for Dag Mitigation | DAGLB, DAGLA, DSG1 | HTR2C 2324/4885HTR2B 2654/4885GABRR1 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.